MARKET

EXAS

EXAS

EXACT Sci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

106.57
-3.13
-2.85%
After Hours: 106.05 -0.52 -0.49% 19:34 10/26 EDT
OPEN
108.35
PREV CLOSE
109.70
HIGH
111.46
LOW
106.33
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
111.46
52 WEEK LOW
35.25
MARKET CAP
16.00B
P/E (TTM)
-102.0492
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
Benzinga · 1d ago
Analysts Estimate Exact Sciences (EXAS) to Report a Decline in Earnings: What to Look Out for
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 4d ago
New Operating Lease Disclosures: The Good, The Bad And The Non-Compliant
Many companies are not complying with the Financial Accounting Standards Board’s (FASB) new standard (ASU 2016-02) for reporting operating lease assets and liabilities on the balance sheet.While companies are better about disclosing the NPV obligation, the two worst areas of disclosure and compliance are future annual payment tables and discount rates.Without compliant disclosures, investors cannot measure the real value of operating lease/ROU asset and liabilities.
Seekingalpha · 10/14 16:00
Exact Sciences Introduces the Oncotype MAP Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer
PR Newswire · 10/12 14:00
Exact Sciences Introduces The Oncotype MAP Pan-Cancer Tissue Test To Help Guide Treatment For Patients With Advanced Cancer
MADISON, Wis., Oct. 12, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced,
Benzinga · 10/12 13:03
Stocks That Would Have Made You Rich Today
Here are the top stocks that you should have invested in.
GOBankingRates · 10/10 19:00
The Daily Biotech Pulse: FDA Panel Review For Alkermes, Axovant Gets Rare Pediatric Disease Designation, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 8)
Benzinga · 10/09 11:20
Exact Sciences schedules third quarter 2020 earnings call
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third quarter 2020 financial results after the close of the U.S. financial markets on October 29, 2020. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
PR Newswire · 10/09 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EXAS. Analyze the recent business situations of EXACT Sci through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EXAS stock price target is 118.67 with a high estimate of 140.00 and a low estimate of 107.00.
EPS
Institutional Holdings
Institutions: 730
Institutional Holdings: 147.14M
% Owned: 97.98%
Shares Outstanding: 150.17M
TypeInstitutionsShares
Increased
170
9.15M
New
175
-456.72K
Decreased
147
7.89M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Conroy
Chief Financial Officer
Jeffrey Elliott
Senior Vice President/Chief Administrative Officer/General Counsel/Secretary
D. Scott Coward
Senior Vice President/Chief Scientific Officer
Graham Lidgard
Senior Vice President
Ana Hooker
Senior Vice President
Scott Johnson
General Manager
Torsten Hoof
General Manager
Jake Orville
General Manager
Gisela Paulsen
General Manager
Mark Stenhouse
Director
Shacey Petrovic
Director
Andrew Slavitt
Independent Director
Thomas Carey
Independent Director
James Doyle
Independent Director
Pierre Jacquet
Independent Director
Daniel Levangie
Independent Director
Freda Lewis-Hall
Independent Director
Kathleen Sebelius
Independent Director
Michael Wyzga
Independent Director
Katherine Zanotti
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EXAS
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of EXACT Sciences Corporation stock information, including NASDAQ:EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.